Spots Global Cancer Trial Database for Sorafenib in Relapsed High Grade Osteosarcoma
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Sorafenib in Relapsed High Grade Osteosarcoma
Official Title: Phase II, Open Label, Non-randomized Study of Second or Third Line Treatment With Sorafenib (BAY 43-9006) in Patients Affected by Relapsed High-grade Osteosarcoma.
Study ID: NCT00889057
Conditions
Interventions
Study Description
Brief Summary: Aim of this exploratory phase II study is to assess the clinical activity of sorafenib as single agent, in terms of percentage of patients with high grade advanced osteosarcoma free from progression following 4 months of therapy
Detailed Description:
Eligibility
Minimum Age: 15 Years
Eligible Ages: CHILD, ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
I.R.C.C. - Unit of Medical Oncology, Candiolo, Torino, Italy
Istituti Ortopedici Rizzoli - Unit of Chemotherapy of Muscoloskeletal Tumors, Bologna, , Italy
Istituto Nazionale Tumori - Unit of Medical Oncology, Milano, , Italy
Ospedale Infantile Regina Margherita - Unit of Paediatric Oncoematology, Torino, , Italy
Contact Details
Name: Massimo Aglietta, MD
Affiliation: I.R.C.C - FPO Candiolo
Role: STUDY_CHAIR
Name: Giovanni Grignani, MD
Affiliation: I.R.C.C. - FPO Candiolo
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
